Bio Path traded at $4.03 this Tuesday July 5th, increasing $0.04 or 1.08 percent since the previous trading session. Looking back, over the last four weeks, Bio Path gained 12.65 percent. Over the last 12 months, its price fell by 36.98 percent. Looking ahead, we forecast Bio Path to be priced at 3.88 by the end of this quarter and at 3.57 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
4.03
Daily Change
1.08%
Yearly
-36.98%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Baxter International 64.57 -0.92 -1.40% -20.35%
Bio Path 4.03 0.04 1.08% -36.98%
Karyopharm Therapeutics 5.10 0.37 7.72% -49.60%
Seattle Genetics 176.60 -3.51 -1.95% 15.80%
Spectrum Pharmaceuticals 0.79 0.02 3.09% -77.65%

Indexes Price Day Year
USND 11182 54.49 0.49% -23.74%
US2000 1716 -12.05 -0.70% -24.57%

Bio Path
Bio-Path Holdings, Inc. is a clinical and preclinical stage oncology company that is focused on the RNAi nanoparticle drug development. The Company’s drug delivery and antisense technology, DNAbilize, is a platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification that is intended to protect the Deoxyribonucleic acid (DNA) from destruction by the body’s enzymes. Its lead drug candidate, prexigebersen, which targets growth factor receptor-bound protein 2 (Grb2), the efficacy portion of a Phase II clinical trial for untreated acute myeloid leukemia (AML) patients in combination with low-dose cytarabine (LDAC). Its second drug candidate, Liposomal Bcl-2 (BP1002), targets the protein Bcl-2, which is responsible for driving cell survival for all cancers. Its third drug candidate, Liposomal STAT3 (BP1003), targets the STAT3 protein and is enabling studies as a potential treatment for pancreatic cancer, non-small cell lung cancer (NSCLC) and AML.